Arcturus Therapeutics - ARCT Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ARCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View ARCT analyst ratings or view top-rated stocks.

8 brokerages have issued twelve-month price targets for Arcturus Therapeutics' shares. Their ARCT share price forecasts range from $8.00 to $98.00. On average, they anticipate the company's stock price to reach $38.75 in the next twelve months. This suggests a possible upside of 157.8% from the stock's current price.
View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts.

Arcturus Therapeutics' stock was trading at $37.01 at the beginning of 2022. Since then, ARCT stock has decreased by 59.4% and is now trading at $15.03.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ARCT earnings forecast.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($1.90) by $1.08. The biotechnology company had revenue of $27.09 million for the quarter, compared to analysts' expectations of $3.33 million. Arcturus Therapeutics had a negative net margin of 407.91% and a negative trailing twelve-month return on equity of 78.54%. During the same quarter last year, the firm posted ($2.07) EPS.

11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Sanofi (SNY).

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Arcturus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (13.40%), State Street Corp (10.56%), ARK Investment Management LLC (8.72%), Sumitomo Mitsui Trust Holdings Inc. (5.44%), Nikko Asset Management Americas Inc. (5.44%) and Point72 Asset Management L.P. (3.44%). Insiders that own company stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Pad Chivukula and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends.

Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARCT stock can currently be purchased for approximately $15.03.

Arcturus Therapeutics (NASDAQ:ARCT) has a market capitalization of $399.50 million and generates $12.40 million in revenue each year. The biotechnology company earns $-203,670,000.00 in net income (profit) each year or ($6.28) on an earnings per share basis.

The company employs 177 workers across the globe.

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.arcturusrx.com. The biotechnology company can be reached via phone at (858) 900-2660 or via email at ir@arcturusrx.com.